8.1 Congenital Heart Defects & Ductal-Dependent Lesions

8.1 Congenital Heart Defects & Ductal-Dependent Lesions

Congenital heart defects (CHDs) represent the most prevalent class of congenital anatomical anomalies, occurring in approximately 8 to 10 per 1,000 live births. In the fetal circulation, gas exchange occurs within the placenta, and high pulmonary vascular resistance (PVR) shunts approximately 90% of right ventricular cardiac output away from non-ventilated lungs through the ductus arteriosus directly into the descending aorta. At delivery, lung expansion and umbilical cord clamping trigger an abrupt fall in PVR and a dramatic rise in systemic vascular resistance (SVR). Concurrently, circulating levels of maternal and placental prostaglandin E2 ($PGE_2$) drop precipitously as the infant's pulmonary vasculature metabolizes circulating eicosanoids. In healthy neonates, exposure to elevated arterial oxygen tension ($PaO_2 > 50\text{--}60\text{ mmHg}$) induces smooth muscle contraction and functional ductal closure within 12 to 24 hours, followed by permanent anatomical obliteration (ligamentum arteriosum) over 2 to 3 weeks.

However, in critical congenital heart disease, postnatal ductal closure disrupts vital blood flow paths, precipitating profound hypoxemia, cardiovascular collapse, or death unless patency of the ductus arteriosus is pharmacologically maintained.

---

Classification of Congenital Heart Defects

Congenital heart defects are traditionally classified by the presence or absence of cyanosis and further categorized by underlying hemodynamics.

                    ┌──────────────────────────────────────────────┐
                    │          Congenital Heart Defects            │
                    └──────────────────────┬───────────────────────┘
                                           │
                 ┌─────────────────────────┴────────────────────────┐
                 ▼                                                  ▼
   ┌───────────────────────────┐                      ┌───────────────────────────┐
   │    Acyanotic Lesions      │                      │     Cyanotic Lesions      │
   │   (Left-to-Right Shunts   │                      │   (Right-to-Left Shunts   │
   │    & Acyanotic Obstruct)  │                      │    & Transposition)       │
   └─────────────┬─────────────┘                      └─────────────┬─────────────┘
                 │                                                  │
     • Ventricular Septal Defect (VSD)                  • Tetralogy of Fallot (TOF)
     • Atrial Septal Defect (ASD)                       • Transposition of Great Arteries (TGA)
     • Patent Ductus Arteriosus (PDA)                   • Tricuspid Atresia (TA)
     • Atrioventricular Septal Defect (AVSD)            • Truncus Arteriosus
     • Coarctation of the Aorta (mild)                  • Total Anomalous Pulm Venous Return
     • Pulmonic / Aortic Stenosis (mild)                • Hypoplastic Left Heart Syndrome (HLHS)

The Hyperoxia Test

When a newborn presents with central cyanosis, distinguishing cyanotic CHD from primary pulmonary parenchymal disease (e.g., respiratory distress syndrome, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn [PPHN]) is critical. The hyperoxia test evaluates arterial blood gas response to 100% fraction of inspired oxygen ($FiO_2$) administered for 10 to 15 minutes:

• Pulmonary Parenchymal Disease: Alveolar ventilation-perfusion ($V/Q$) mismatch or diffusion limitation is partially or fully overcome by 100% oxygen, driving $PaO_2$ above $150\text{ to } 300\text{ mmHg}$.
• Cyanotic Congenital Heart Defect: Due to a fixed anatomical right-to-left intracardiac or extracardiac shunt, deoxygenated systemic venous blood bypasses the pulmonary bed entirely. The $PaO_2$ remains severely depressed—typically $< 100\text{ mmHg}$ (and frequently $< 50\text{ to } 60\text{ mmHg}$) with minimal or no rise in pulse oximetry saturation ($SpO_2$).

---

Ductal-Dependent Lesions: Hemodynamic Taxonomy

Ductal-dependent cardiac lesions represent true pediatric emergencies. They are categorized into three distinct pathophysiological groups based on the vascular circuit sustained by the patent ductus arteriosus.

1. Ductal-Dependent Pulmonary Blood Flow

In these lesions, anatomical obstruction of the right ventricular outflow tract prevents systemic venous blood from reaching the pulmonary capillary bed via the pulmonary valve. Blood reaches the lungs solely via left-to-right flow through the ductus arteriosus (aorta $\rightarrow$ pulmonary artery).

• Key Anatomical Lesions:
  • Pulmonary Atresia (with intact ventricular septum or with VSD)
  • Critical Pulmonary Valve Stenosis
  • Tricuspid Atresia
  • Severe Tetralogy of Fallot (with severe infundibular or valvular pulmonary stenosis)
  • Ebstein Anomaly (severe form with functional pulmonary atresia)
• Clinical Presentation: As the ductus constricts within the first hours to days of life, pulmonary perfusion drops precipitously. The infant manifests profound, progressive cyanosis refractory to supplemental oxygen, tachypnea without prominent retractions, metabolic acidosis, and rapid hypoxemic arrest.
• Therapeutic Goal: Re-open and maintain ductal patency to restore pulmonary blood flow and normalize systemic arterial oxygen delivery.

2. Ductal-Dependent Systemic Blood Flow

In these lesions, severe left ventricular outflow tract obstruction prevents oxygenated blood from leaving the left ventricle to supply the systemic arterial circulation. Systemic perfusion is maintained entirely via right-to-left flow through the ductus arteriosus (pulmonary artery $\rightarrow$ descending aorta $\rightarrow$ systemic vascular beds).

• Key Anatomical Lesions:
  • Hypoplastic Left Heart Syndrome (HLHS): Marked hypoplasia of the left ventricle, mitral valve, aortic valve, and ascending aorta.
  • Critical Aortic Valve Stenosis
  • Interrupted Aortic Arch (IAA)
  • Severe / Critical Coarctation of the Aorta
• Clinical Presentation: In utero and immediately post-birth, the infant appears deceptively well. As the PDA constricts at 24 to 72 hours, systemic cardiac output collapses. The infant presents with pallor, mottled cool extremities, weak or absent femoral pulses, prolonged capillary refill (>4 seconds), oliguria/anuria, severe metabolic lactic acidosis, and rapid progression to cardiogenic shock.
• Therapeutic Goal: Maintain ductal patency to sustain systemic perfusion; balance systemic and pulmonary vascular resistances ($Q_p:Q_s \approx 1:1$) to avoid pulmonary overcirculation and systemic steal.

3. Parallel Circulations (D-Transposition of the Great Arteries)

In D-Transposition of the Great Arteries (D-TGA), ventriculoarterial discordance exists: the aorta arises from the morphologic right ventricle, and the pulmonary artery arises from the morphologic left ventricle. This configuration creates two separate, parallel, closed circulatory loops:

1. Systemic loop: Systemic veins $\rightarrow$ Right atrium $\rightarrow$ Right ventricle $\rightarrow$ Aorta $\rightarrow$ Body $\rightarrow$ Systemic veins (deoxygenated blood recirculates).
2. Pulmonary loop: Pulmonary veins $\rightarrow$ Left atrium $\rightarrow$ Left ventricle $\rightarrow$ Pulmonary artery $\rightarrow$ Lungs $\rightarrow$ Pulmonary veins (oxygenated blood recirculates).

Survival is entirely impossible without bidirectional mixing sites: an atrial septal defect (ASD/PFO), a ventricular septal defect (VSD), or a patent ductus arteriosus (PDA). PGE1 infusion maintains ductal patency, expanding intracardiac mixing. If mixing across the atrial septum is restrictive, emergent bedside balloon atrial septostomy (Rashkind procedure) is mandatory.

---

Prostaglandin E1 (Alprostadil / PGE1) Pharmacology & Therapeutics

Alprostadil (synthetic Prostaglandin E1) is the cornerstone medical countermeasure for ductal-dependent congenital heart defects.

Mechanism of Action & Hemodynamic Dynamics

Alprostadil binds directly to $EP_4$ prostanoid receptors on the vascular smooth muscle of the ductus arteriosus. Receptor activation stimulates membrane-bound adenylyl cyclase, driving an intracellular accumulation of cyclic adenosine monophosphate (cAMP). Elevated cAMP reduces intracellular free calcium concentration, causing profound relaxation and dilation of the ductal smooth muscle.

• Response Timing: In a closed or severely constricted ductus, smooth muscle relaxation begins within 10 to 30 minutes of initiating IV infusion. Arterial oxygen tension increases by 15 to 30 mmHg in pulmonary lesions, while systemic arterial pressure and femoral pulses normalize in systemic lesions.
• Responsiveness Window: Ductal smooth muscle is highly responsive to PGE1 in neonates $< 7\text{ to } 14\text{ days of age}$. Beyond 2 to 3 weeks of life, anatomical remodeling (fibrosis, subendothelial intimal proliferation) limits pharmacologic dilation, although trials of high-dose PGE1 remain clinically indicated during emergencies.

Dosing Protocols & Administration

• Initial Opening Dose: $0.05\text{ to }0.1\text{ mcg/kg/min}$ continuous intravenous infusion.
• Rapid Down-Titration (Maintenance Dose): As soon as ductal patency is established—demonstrated by improved $SpO_2$ (75%–85% in pulmonary lesions), palpable femoral pulses, base deficit normalization, and echocardiographic confirmation—the infusion must be rapidly titrated downward to $0.01\text{ to }0.025\text{ mcg/kg/min}$.
• Refractory Cases: If initial response is absent after 15 to 30 minutes, the infusion may be transiently escalated to $0.2\text{ mcg/kg/min}$ while preparing for urgent catheter-based or surgical intervention.

                      PGE1 Infusion Protocol Architecture

[Suspected Ductal-Dependent Lesion]
               │
               ▼
[Initiate PGE1 at 0.05 - 0.1 mcg/kg/min IV Continuous Infusion]
               │
               ├─────────────────────────────────────────┐
               ▼                                         ▼
   [Clinical Response within 15-30 min]     [No Response after 15-30 min]
   • SpO2 75-85% (pulmonary lesions)         • Increase dose to 0.2 mcg/kg/min
   • Femoral pulses palpable (systemic)      • Confirm line patency & IV site
   • Lactate clearing, urine >1 mL/kg/h      • Urgent echocardiogram / catheterization
               │
               ▼
[Titrate Down to Maintenance: 0.01 - 0.025 mcg/kg/min]
   • Minimizes dose-dependent adverse effects (apnea, hypotension, fever)
   • Maintain continuous infusion until definitive surgical/catheter palliation

Pharmacokinetics & Routes of Infusion

• Half-Life: Ultra-short terminal half-life ($t_{1/2} < 1\text{ minute}$) due to extensive first-pass metabolism (60% to 90%) by 15-hydroxyprostaglandin dehydrogenase in the pulmonary vascular bed. Consequently, PGE1 must be delivered as a continuous intravenous infusion; any accidental line interruption results in acute ductal constriction within minutes.
• Infusion Sites: PGE1 can be infused via a peripheral IV line, umbilical venous catheter (UVC), or central venous line. Umbilical artery catheters (UAC) placed with the tip at the ductus level have been utilized historically, but intravenous delivery is equally effective and carries lower thrombotic risk. Intra-arterial infusion must be avoided peripherally due to severe localized vasoconstriction/erythema.

Adverse Effect Profile & Proactive Management

[!WARNING] In Ductal-Dependent Systemic Lesions (e.g., HLHS): Excessive Oxygen is Toxic. High concentrations of supplemental oxygen act as a potent pulmonary vasodilator while mildly constricting ductal tissue. In an infant with HLHS, lowering PVR causes massive pulmonary overcirculation at the expense of systemic perfusion ("pulmonary steal"), precipitating profound cardiogenic shock and metabolic acidosis. In ductal-dependent systemic lesions, maintain ambient oxygen or target mild sub-ambient therapy to achieve target $SpO_2$ of 75% to 85% and a balanced $Q_p:Q_s$ ratio of 1:1.

---

Single-Ventricle Staged Palliation Pathways

Infants born with single-ventricle physiology—most notably Hypoplastic Left Heart Syndrome (HLHS), double-inlet left ventricle, or severe tricuspid atresia—cannot undergo biventricular anatomical repair. Instead, they undergo a staged three-step surgical palliation pathway designed to divert systemic venous blood passively into the pulmonary arterial bed, dedicating the single morphologic ventricle exclusively to driving systemic circulation.

          Single-Ventricle Surgical Staged Palliation Paradigm (HLHS Model)

    Stage 1: Norwood / Sano (Neoaorta + Systemic-to-Pulmonary Shunt)
             [Timing: First 1-2 Weeks of Life]
             • Connects RV to reconstructed neoaorta
             • Unrestricted atrial communication (atrial septectomy)
             • Pulmonary blood flow via mBT shunt or Sano conduit
             • High interstage mortality; Aspirin 1-5 mg/kg/day mandatory
                            │
                            ▼
    Stage 2: Bidirectional Glenn (Superior Cavopulmonary Anastomosis)
             [Timing: 4 - 6 Months of Age]
             • Shunt takedown; SVC anastomosed directly to Pulmonary Artery
             • Decompresses single ventricle (reduces volume overload)
             • In-line pulmonary blood flow from upper body
                            │
                            ▼
    Stage 3: Fontan Completion (Total Cavopulmonary Connection)
             [Timing: 2 - 4 Years of Age (Weight ~12-15 kg)]
             • IVC flow redirected to Pulmonary Artery (extracardiac conduit)
             • Completely separates oxygenated and deoxygenated circuits
             • Entire pulmonary blood flow is passive (non-pulsatile, no subpulmonary pump)
             • High lifelong risk of thrombosis, PLE, and plastic bronchitis

Stage 1: Norwood Procedure (with mBT Shunt or Sano Conduit)

• Timing: Performed within the first 1 to 2 weeks of life.
• Surgical Components:
  1. The diminutive native aorta and main pulmonary trunk are joined to construct a large neoaorta, allowing the right ventricle to pump blood unobstructed into the systemic and coronary circulations.
  2. An atrial septectomy is performed to ensure unobstructed pulmonary venous return into the single ventricle.
  3. Controlled pulmonary blood flow is established using either:
     • Modified Blalock-Taussig (mBT) Shunt: A synthetic polytetrafluoroethylene (PTFE) Gore-Tex tube (typically 3.0 to 3.5 mm diameter) placed between the right subclavian artery and the right pulmonary artery (systemic-to-pulmonary shunt).
     • Sano Shunt (RV-to-PA Conduit): A PTFE conduit connecting the right ventricle directly to the pulmonary artery bifurcation. The Sano shunt avoids the diastolic run-off (coronary steal) associated with the mBT shunt.

Stage 2: Bidirectional Glenn Procedure

• Timing: Performed at 4 to 6 months of age, once pulmonary vascular resistance has reached physiological nadir.
• Surgical Components: The mBT shunt or Sano conduit is taken down, and the superior vena cava (SVC) is anastomosed end-to-side directly onto the right pulmonary artery. Venous blood from the head and upper extremities flows passively into both lungs. This offloads volume burden from the single ventricle.

Stage 3: Fontan Procedure (Total Cavopulmonary Connection)

• Timing: Performed at 2 to 4 years of age (patient weight typically 12 to 15 kg).
• Surgical Components: The inferior vena cava (IVC) blood is routed directly into the pulmonary artery, typically via a prosthetic extracardiac conduit (or intra-atrial lateral tunnel). A small fenestration (4 to 5 mm hole) is often created between the conduit and the common atrium to act as a pop-off valve during periods of acute pulmonary pressure spikes, preserving cardiac output at the expense of mild cyanosis.
• Physiology: Following the Fontan, both SVC and IVC blood flows passively through the pulmonary vascular bed without any subpulmonary pumping chamber. Central venous pressure (CVP) equals pulmonary arterial pressure (typically 12 to 16 mmHg).

---

Antithrombotic Management Across Palliation Stages

Children with single-ventricle physiology exist in an abnormal, prothrombotic hemodynamic environment characterized by synthetic prosthetic grafts, sluggish low-shear venous flow, polycythemia secondary to chronic hypoxemia, endothelial dysfunction, and progressive hepatic congestion.

Stage 1 (Interstage) Antithrombotic Management

• The Risk: Acute mBT shunt thrombosis is a devastating, sudden event with mortality exceeding 50%. Platelet activation across the small-caliber (3.0–3.5 mm) synthetic PTFE graft lumen triggers platelet-rich white thrombi.
• Standard Prophylaxis: Low-dose aspirin ($1\text{ to }5\text{ mg/kg/day}$, typically administered as $20.25\text{ to }40.5\text{ mg}$ once daily or $81\text{ mg}$ once daily in older infants) is the standard of care recommended by the American Heart Association (AHA) and Pediatric Heart Network trials.
• Aspirin Resistance & Escalation: In infants exhibiting shunt stenosis or high clinical suspicion of aspirin failure, clopidogrel ($0.2\text{ mg/kg/day}$, titrating to platelet inhibition targets) may be added or substituted. Prophylactic enoxaparin ($0.5\text{ mg/kg/dose}$ subQ every 12 hours targeting anti-Xa $0.2\text{--}0.4\text{ units/mL}$) is utilized in high-risk postoperative intervals.

Glenn & Fontan Anticoagulation Strategies

In the Fontan circulation, sluggish non-pulsatile venous flow, atrial dilation, and high rates of protein-losing enteropathy (PLE)—which causes catastrophic enteric loss of endogenous anticoagulants (antithrombin III, protein C, and protein S)—produce a cumulative lifetime thromboembolism risk of 10% to 33%.

• Standard Thromboprophylaxis: Long-term aspirin ($81\text{ mg/day}$) is standard in low-risk Fontan patients.
• Full Anticoagulation Indications: Warfarin (target INR 2.0 to 3.0) or therapeutic enoxaparin is mandatory in patients with:
  • Persistent conduit fenestrations (risk of paradoxical systemic arterial embolic stroke)
  • History of previous thromboembolism
  • Atrial tachyarrhythmias (intra-atrial reentrant tachycardia [IART])
  • Evident intracardiac thrombus or severe ventricular dysfunction ($EF < 30%$)
• Direct Oral Anticoagulants (DOACs): The UNIVERSE trial and expanding pediatric evidence support rivaroxaban and apixaban for thromboprophylaxis in stable post-Fontan pediatric patients, providing predictable anticoagulation without routine INR monitoring.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: When an infant presents with suspected coarctation of the aorta or HLHS, never administer high concentrations of supplemental oxygen. Oxygen drops PVR, steals blood from the systemic circulation into the lungs, and precipitates severe anuria and cardiogenic shock. Maintain $SpO_2$ at 75% to 85%.
• Exam Trap 2: Do not mistake PGE1-induced hyperpyrexia for systemic neonatal bacterial sepsis. While blood cultures should be obtained if sepsis is clinically plausible, an isolated temperature spike to 38.5°C within 2 hours of initiating PGE1 without hemodynamic decompensation is a well-known eicosanoid effect.
• Board Rule: Always prepare for endotracheal intubation before initiating alprostadil. Apnea occurs in up to 12% of patients; lack of immediate airway readiness is considered a major patient safety violation on the BCPPS exam.